Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Margaret Tonda"'
Autor:
Satheesh Chonat, Earl Fields, Hannah Baratz, Amanda Watt, Mira Pochron, Sandy Dixon, Margaret Tonda, Clark Brown, David Archer
Publikováno v:
eJHaem, Vol 5, Iss 1, Pp 125-130 (2024)
Abstract Introduction: Sickle haemoglobin (HbS) polymerisation perturbs red blood cell (RBC) rheology and drives sickle cell disease (SCD) pathophysiology. Voxelotor is an HbS polymerisation inhibitor that increases haemoglobin (Hb)–oxygen affinity
Externí odkaz:
https://doaj.org/article/d85d9eb3edf449ed8d418c775d96b9ae
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 698-710 (2022)
Abstract Sickle cell disease (SCD) is characterized by the production of sickle hemoglobin (HbS), which when deoxygenated, polymerizes leading to red blood cell damage and hemolytic anemia, a defining feature of SCD. Voxelotor (Oxbryta) is a small mo
Externí odkaz:
https://doaj.org/article/6c72c21a581d402dbe39f18f86468896
Autor:
Paul Telfer, Irene Agodoa, Kathleen M. Fox, Laurie Burke, Timothy Mant, Marzena Jurek, Margaret Tonda, Josh Lehrer-Graiwer
Publikováno v:
Hematology Reports, Vol 10, Iss 2 (2018)
For many patients with sickle cell disease (SCD), jaundice is a significant clinical disease manifestation that impacts on patient well-being. We report a case of a patient with SCD and chronic jaundice treated with voxelotor (GBT440), a novel small
Externí odkaz:
https://doaj.org/article/5a6a888f058a4f77855c543547925246
Publikováno v:
Expert review of hematology. 15(6)
Sickle cell disease (SCD) describes a group of heritable blood disorders caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to anemia and vaso-occlusion, a process that impedes delivery of oxygen to tissues throughout t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c92fdee934e3f6e052cbf3ef708b7b89
https://pubmed.ncbi.nlm.nih.gov/35671094
https://pubmed.ncbi.nlm.nih.gov/35671094
Autor:
Maureen Achebe, Sarah Gray, Kenneth I. Ataga, Hoda Hassab, Amal El-Beshlawy, Elliott Vichinsky, Margaret Tonda, Videlis Nduba, Irene Agodoa, Jo Howard, Robert Clark Brown, Joshua Lehrer-Graiwer
Publikováno v:
The Lancet Haematology. 8:e323-e333
For decades, patients with sickle cell disease have had only a limited number of therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin polymerisation inhibitor, was approved in the USA for the treatment of sickle ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9f65fcf8ec26745fd1e15dc57df93b
https://doi.org/10.1016/s2352-3026(21)00059-4
https://doi.org/10.1016/s2352-3026(21)00059-4
Autor:
Jeremie H. Estepp, Ram Kalpatthi, Gerald Woods, Sara Trompeter, Robert I. Liem, Kacie Sims, Adlette Inati, Baba P. D. Inusa, Andrew Campbell, Connie Piccone, Miguel R. Abboud, Kim Smith‐Whitley, Sandra Dixon, Margaret Tonda, Carla Washington, Noelle M. Griffin, Clark Brown
Publikováno v:
Pediatric bloodcancerREFERENCES. 69(8)
Sickle cell disease (SCD) is a devastating, multisystemic disorder that affects millions of people worldwide. The earliest clinical manifestations of SCD can affect infants as young as 6 months of age, and pediatric patients are at risk for acute and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b835fbea22aeea9f29a9f29b7cd3d91
https://pubmed.ncbi.nlm.nih.gov/35686738
https://pubmed.ncbi.nlm.nih.gov/35686738
Autor:
Bart J. Biemond, Joshua Lehrer-Graiwer, Sarah Gray, Jennifer Knight-Madden, Caterina P. Minniti, Margaret Tonda
Publikováno v:
American Journal of Hematology
American journal of hematology, 96(4), E126-E128. Wiley-Liss Inc.
American journal of hematology, 96(4), E126-E128. Wiley-Liss Inc.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06990b47f01d8c491b31bc83ce8c3693
http://europepmc.org/articles/PMC7986764
http://europepmc.org/articles/PMC7986764
Autor:
Vincent Siu, Timothy Mant, Mira Patel, Noel Landsman, Joshua Lehrer-Graiwer, Moji Awogbade, Kobina Dufu, John B. Porter, Daniel D. Gretler, Athiwat Hutchaleelaha, Sandra V. Dixon, Claire Hemmaway, Paul Telfer, D. Mark Layton, Jo Howard, Margaret Tonda
Publikováno v:
Blood. 133:1865-1875
New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe morbidity and early mortality associated with the disease. Voxeloto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7890326c7b563b083e7615d4cfa0cca0
https://doi.org/10.1182/blood-2018-08-868893
https://doi.org/10.1182/blood-2018-08-868893
Autor:
R. Clark Brown, Victor R. Gordeuk, Sarah Gray, Maureen Achebe, Hoda Hassab, Bart J. Biemond, Paul Telfer, Salam Alkindi, Thokozeni Lipato, Margaret Tonda, Joanna Howard
Publikováno v:
Blood. 138:3114-3114
Background: Sickle cell disease (SCD) is a lifelong, inherited blood disorder, resulting from a mutation in the hemoglobin (Hb) subunit β gene, that leads to sickle hemoglobin (HbS) formation. Polymerization of HbS causes red blood cell sickling and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63e74afb37e23af7924615f6ae96428c
https://doi.org/10.1182/blood-2021-153582
https://doi.org/10.1182/blood-2021-153582
Autor:
Victor R. Gordeuk, Kenneth I. Ataga, Elliott Vichinsky, Irene Agodoa, Margaret Tonda, Adlette Inati, Paul Telfer, Sarah Gray
Publikováno v:
Blood. 136:31-32
Background: Sickle cell disease (SCD) is a lifelong, inherited disorder characterized by sickle hemoglobin (HbS) polymerization that results in red blood cell (RBC) sickling and results in complications such as hemolytic anemia, vaso-occlusive crises
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c59fc355326600220fd105582954971
https://doi.org/10.1182/blood-2020-140863
https://doi.org/10.1182/blood-2020-140863